Literature DB >> 27798871

Radiotherapy-associated Furin Expression and Tumor Invasiveness in Recurrent Laryngeal Cancer.

Myungjin Lee1, Chang Hwan Ryu2, Hyo Won Chang1, Gui Chul Kim1, Seong Who Kim3, Sang Yoon Kim4,5.   

Abstract

BACKGROUND/AIM: Recurrent laryngeal cancer often shows an aggressive phenotype after radiotherapy and does not respond to conventional therapeutic strategies. In this study, we investigated the contribution of furin to cellular invasiveness in radio-resistant laryngeal cancer.
MATERIALS AND METHODS: Using previously established AMC-HN-3 and AMC-HN-8 cell lines from laryngeal carcinoma patients, recurrent laryngeal cancer models were generated by cumulative irradiation (AMC-HN-3-70Gy and AMC-HN-8-70Gy). Immunocytochemistry and western blotting were used to determine the epithelial-mesenchymal transition (EMT). Invasion capacity was assessed using an in vitro invasion assay. Zymography was used to assess metalloproteinase-2 (MMP-2) activity. Tumor xenografts were developed to compare growth rate and furin expression in vivo. Furin expression in 35 patients (45 samples) with salvage total laryngectomy after radiation-based treatment was assessed by laryngeal cancer tissue microarray.
RESULTS: Both AMC-HN-3-70Gy and AMC-HN-8-70Gy cell lines underwent EMT following radiation. However, AMC-HN-3-70Gy cells showed increased cellular invasiveness, whereas AMC-HN-8-70Gy cells showed no difference. AMC-HN-3-70Gy cells also exhibited elevated furin expression with up-regulated expression of the active form of membrane type 1-matrix metalloproteinase (MT1-MMP)/MMP-2, whereas AMC-HN-8-70Gy cells did not show significant changes. After administration of a furin inhibitor (chloromethyl ketone (CMK)), AMC-HN-3-70Gy cells showed a significant decrease in MT1-MMP/MMP-2 expression and cellular invasiveness. Nine of 22 samples (40.9%) from salvage total laryngectomy and one of 13 pre-radiation samples (7.7%) had high furin expression. Post-radiation, furin expression increased in seven of 10 patients whose pre- and post-radiation samples were available; all-cancer mortality (three patients) was observed in this group.
CONCLUSION: Together with EMT, furin activity may serve as an indicator of an aggressive cancer phenotype, suggesting that furin is a potentially useful target for recurrent laryngeal cancer. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  MMP-2; MT1-MMP; Radiotherapy; furin; invasion; laryngeal cancer

Mesh:

Substances:

Year:  2016        PMID: 27798871     DOI: 10.21873/anticanres.11081

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Identification of a Six-Gene Signature for Predicting the Overall Survival of Cervical Cancer Patients.

Authors:  Xiao Huo; Xiaoshuang Zhou; Peng Peng; Mei Yu; Ying Zhang; Jiaxin Yang; Dongyan Cao; Hengzi Sun; Keng Shen
Journal:  Onco Targets Ther       Date:  2021-02-05       Impact factor: 4.147

2.  Increased susceptibility of SARS-CoV2 infection on oral cancer patients; cause and effects: An hypothesis.

Authors:  Anshika Chauhan; Sushmita Ghoshal; Arnab Pal
Journal:  Med Hypotheses       Date:  2020-06-09       Impact factor: 1.538

Review 3.  Furin-mediated protein processing in infectious diseases and cancer.

Authors:  Elisabeth Braun; Daniel Sauter
Journal:  Clin Transl Immunology       Date:  2019-08-05

4.  Ionizing radiation increases the endothelial permeability and the transendothelial migration of tumor cells through ADAM10-activation and subsequent degradation of VE-cadherin.

Authors:  Pascaline Nguemgo Kouam; Günther A Rezniczek; Irenäus A Adamietz; Helmut Bühler
Journal:  BMC Cancer       Date:  2019-10-16       Impact factor: 4.430

Review 5.  Combined Radiochemotherapy: Metalloproteinases Revisited.

Authors:  Verena Waller; Martin Pruschy
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

6.  Pan-Cancer Analysis of FURIN as a Potential Prognostic and Immunological Biomarker.

Authors:  Bolun Zhou; Shugeng Gao
Journal:  Front Mol Biosci       Date:  2021-04-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.